Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first‐line combination antiretroviral therapy

The aim of the study was to assess the impact of rapid and sustained viral control produced by combination antiretroviral therapy (cART) on HIV‐associated immune activation and inflammation.

[1]  M. Lederman,et al.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. , 2014, The Journal of infectious diseases.

[2]  M. Lederman,et al.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.

[3]  M. Lederman,et al.  Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection , 2014, AIDS.

[4]  G. Carcelain,et al.  Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study , 2014, BMC Infectious Diseases.

[5]  P. Sax,et al.  Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 , 2014, Journal of acquired immune deficiency syndromes.

[6]  D. Lauffenburger,et al.  HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways , 2013, AIDS.

[7]  A. d’Arminio Monforte,et al.  The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study , 2013, BMC Infectious Diseases.

[8]  M. Lederman,et al.  Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. , 2013, The Journal of antimicrobial chemotherapy.

[9]  D. Richman,et al.  Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs , 2013, The Lancet.

[10]  M. Fischl,et al.  Immune Activation in HIV-Infected Aging Women on Antiretrovirals—Implications for Age-Associated Comorbidities: A Cross-Sectional Pilot Study , 2013, PloS one.

[11]  R. Bosch,et al.  CD8+ T-Cell Activation in HIV-1–Infected Patients Experiencing Transient Low-level Viremia During Antiretroviral Therapy , 2013, Journal of acquired immune deficiency syndromes.

[12]  J. Goedert,et al.  Markers of microbial translocation and risk of AIDS-related lymphoma , 2013, AIDS.

[13]  F. Barré-Sinoussi,et al.  Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection , 2012, PloS one.

[14]  L. Kuller,et al.  Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals , 2012, PloS one.

[15]  D. Douek,et al.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities , 2012, Nature Reviews Microbiology.

[16]  P. Sax,et al.  Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir , 2012, AIDS.

[17]  Curtis Cooper,et al.  Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. , 2012, The Journal of infectious diseases.

[18]  K. Gianesin,et al.  Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  Cheng Li,et al.  A Plasma Biomarker Signature of Immune Activation in HIV Patients on Antiretroviral Therapy , 2012, PloS one.

[20]  M. Lederman,et al.  Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. , 2011, The Journal of infectious diseases.

[21]  C. Katlama,et al.  Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients , 2011, AIDS.

[22]  Mardge H. Cohen,et al.  The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women , 2011, AIDS.

[23]  D. Boulware,et al.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. , 2011, The Journal of infectious diseases.

[24]  Jeffrey N. Martin,et al.  Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. , 2011, The Journal of infectious diseases.

[25]  Handan Wand,et al.  Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.

[26]  Richard D Moore,et al.  CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? , 2010, AIDS research and therapy.

[27]  M. Lederman,et al.  Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients , 2010, PloS one.

[28]  G. Poli,et al.  Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. , 2010, The Journal of infectious diseases.

[29]  S. Gange,et al.  Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study , 2010, AIDS.

[30]  P. Massip,et al.  HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy , 2009, PloS one.

[31]  D. Fine,et al.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment , 2009, AIDS.

[32]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[33]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[34]  V. Appay,et al.  Immune activation and inflammation in HIV‐1 infection: causes and consequences , 2008, The Journal of pathology.

[35]  D. Costagliola,et al.  Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV , 2004, AIDS.

[36]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[37]  C. Boucher,et al.  The Dominant Source of CD4+ and CD8+ T‐Cell Activation in HIV Infection Is Antigenic Stimulation , 2000, Journal of acquired immune deficiency syndromes.

[38]  J. Brenchley,et al.  Microbial translocation, immune activation, and HIV disease. , 2013, Trends in microbiology.

[39]  Jeffrey N. Martin,et al.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. , 2008, The Journal of infectious diseases.